{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Lemiale V"],"funding":["Fisher &amp; Paykel"],"pagination":["380"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC4629403"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["19"],"pubmed_abstract":["<h4>Introduction</h4>In immunocompromised patients, acute respiratory failure (ARF) is associated with high mortality, particularly when invasive mechanical ventilation (IMV) is required. In patients with severe hypoxemia, high-flow nasal oxygen (HFNO) therapy has been used as an alternative to delivery of oxygen via a Venturi mask. Our objective in the present study was to compare HFNO and Venturi mask oxygen in immunocompromised patients with ARF.<h4>Methods</h4>We conducted a multicenter, parallel-group randomized controlled trial in four intensive care units. Inclusion criteria were hypoxemic ARF and immunosuppression, defined as at least one of the following: solid or hematological malignancy, steroid or other immunosuppressant drug therapy, and HIV infection. Exclusion criteria were "],"journal":["Critical care (London, England)"],"pubmed_title":["The effects of a 2-h trial of high-flow oxygen by nasal cannula versus Venturi mask in immunocompromised patients with hypoxemic acute respiratory failure: a multicenter randomized trial."],"pmcid":["PMC4629403"],"funding_grant_id":["provide oxygen and HFNC devices"],"pubmed_authors":["Azoulay E","Demoule A","Mayaux J","Rabbat A","Lemiale V","Lambert J","Mokart D"],"additional_accession":[]},"is_claimable":false,"name":"The effects of a 2-h trial of high-flow oxygen by nasal cannula versus Venturi mask in immunocompromised patients with hypoxemic acute respiratory failure: a multicenter randomized trial.","description":"<h4>Introduction</h4>In immunocompromised patients, acute respiratory failure (ARF) is associated with high mortality, particularly when invasive mechanical ventilation (IMV) is required. In patients with severe hypoxemia, high-flow nasal oxygen (HFNO) therapy has been used as an alternative to delivery of oxygen via a Venturi mask. Our objective in the present study was to compare HFNO and Venturi mask oxygen in immunocompromised patients with ARF.<h4>Methods</h4>We conducted a multicenter, parallel-group randomized controlled trial in four intensive care units. Inclusion criteria were hypoxemic ARF and immunosuppression, defined as at least one of the following: solid or hematological malignancy, steroid or other immunosuppressant drug therapy, and HIV infection. Exclusion criteria were ","dates":{"release":"2015-01-01T00:00:00Z","publication":"2015 Nov","modification":"2025-05-31T23:30:32.472Z","creation":"2019-03-27T02:01:10Z"},"accession":"S-EPMC4629403","cross_references":{"pubmed":["26521922"],"doi":["10.1186/s13054-015-1097-0"]}}